Том 19 № 2 (2015)
ОБЗОРЫ

Периоперационное использование левосимендана в кардиохирургии

PDF
  • В. Ломиворотов,
  • А. Еременко,
  • В. Бобошко,
  • М. Абубакиров
В. Ломиворотов
ФГБУ «ННИИПК им. акад. Е.Н. Мешалкина» Минздрава России
Bio
А. Еременко
ФГБУ «Российский научный центр хирургии им. акад. Б.В. Петровского»
Bio
В. Бобошко
ФГБУ «ННИИПК им. акад. Е.Н. Мешалкина» Минздрава России
Bio
М. Абубакиров
ФГБУ «ННИИПК им. акад. Е.Н. Мешалкина» Минздрава России
Bio
DOI: https://doi.org/10.21688/1681-3472-2015-2-113-123

Опубликован 17.07.2015

Ключевые слова

  • Кардиохирургия,
  • Аортокоронарное шунтирование,
  • Операции на клапанах сердца,
  • Синдром низкого сердечного выброса,
  • Левосимендан

Как цитировать

Ломиворотов, В., Еременко, А., Бобошко, В., & Абубакиров, М. (2015). Периоперационное использование левосимендана в кардиохирургии. Патология кровообращения и кардиохирургия, 19(2), 113–123. https://doi.org/10.21688/1681-3472-2015-2-113-123

Copyright (c) 2015 Ломиворотов В.В., Еременко А.А., Бобошко В.А., Абубакиров М.Н.

Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.

Аннотация

Продемонстрировано, что низкий сердечный выброс в послеоперационном периоде служит предиктором развития органной дисфункции и летальности у кардиохирургических пациентов. В течение многих лет стандартом терапии служили катехоламины, несмотря на то что они обладают значительным риском нежелательных явлений со стороны сердца и других органов, а их применение сопровождается повышением смертности. С другой стороны, показано, что левосимендан, действие которого заключается в повышении чувствительности к ионам кальция и открытии калиевых каналов, улучшает функцию сердца, не нарушая баланс потребления кислорода, а также оказывает защитные эффекты в отношении других органов. В ряде клинических исследований обнаружены благоприятные кардиогенные и некардиогенные эффекты периоперационного использования левосимендана. Целью обзора явилось рассмотрение механизмов действия левосимендана, а также обобщение современных данных клинического применения препарата.

PDF

Библиографические ссылки

  1. Ahmed I., House C.M., Nelson W.B. Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB) // J. Cardiothorac. Surg. 2009. Vol. 4. P. 24.
  2. Rudiger A., Businger F., Streit M., Schmid E.R., Maggiorini M., Follath F. Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure // Swiss Med. Wkly. 2009. Vol. 139. P. 110–116.
  3. Rao V., Ivanov J., Weisel R.D., Ikonomidis J.S., Christiakis G.T., David T.E. Predictors of low cardiac output syndrome after coronary artery bypass // J. Thorac. Cardiovasc. Surg. 1996. Vol. 112. P. 38–51.
  4. Açil T., Türköz R., Açil M. et al. Value of prolonged QRS duration as a predictor of low cardiac output syndrome in patients with impaired left ventricular systolic function who undergo isolated coronary artery bypass grafting // Am. J. Cardiol. 2006. Vol. 9. P. 1357–1362.
  5. Hobson C.E., Yavas S., Segal M.S. et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery // Circulation. 2009. Vol. 119. P. 2444–2453.
  6. Ronco C., Haapio M., House A., Anavekar N., Bellomo R., Car-diorenal syndrome // J. Am. Coll. Cardiol. 2008. Vol. 52. P. 1527–1539.
  7. Nielsen D.V., Hansen M.K., Johnsen S.P., Hansen M., Hindsholm K., Jakobsen C.H.J. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score matched analysis // Anesthesiology. 2014. Vol. 120. P. 1098–1108.
  8. Papp Z., Édes I., Fruhwald S. et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan // Int. J. Cardiol. 2012. Vol. 159. P. 82–87.
  9. Eriksson O., Pollesello P., Haikala H., Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion // J. Cardiovasc. Pharmacol. 2004 Vol. 44. P. 316–321.
  10. Lepran I., Pollesello P., Vajda S., Varró A., Papp J.G. Preconditioning effects of levosimendan in a rabbit cardiac ischemia–reperfusion model // J. Cardiovasc. Pharmacol. 2006. Vol. 48. P. 148–152.
  11. duToit E.F., Genis A., Opie L.H., Pollesello P., Lochner A. A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea-pig heart // Br. J. Pharmacol. 2008. Vol. 154. P. 41–50.
  12. Jamali I.N., Kersten J.R., Pagel P.S., Hettrick D.A., Warltier D.C. Intracoronary levosimendan enhances contractile function of stunned myocardium // Anesth. Analg. 1997. Vol. 85. P. 23–29.
  13. Levijoki J., Pollesello P., Kaheinen P., Haikala H. Improved survival with simendan after experimental myocardial infarction in rats // Eur. J. Pharmacol. 2001. Vol. 419. P. 243–248.
  14. Harrison R.W., Hasselblad V., Mehta R.H., Levin R. Harrington R.A., Alexander J.H. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis // J. Cardiothorac. Vasc. Anesth. 2013. Vol. 27. P. 1224–1232.
  15. Zingman L.V., Alekseev A.E., Hodgson-Zingman D.M. Terzic A. ATP-sensitive potassium channels: metabolic sensing and cardioprotection // J. Appl. Physiol. 2007. 103. P. 1888–1893.
  16. McCully J.D., Levitsky S. Mitochondrial ATP-sensitive potassium channels in surgical cardioprotection // Arch. Biochem. Biophys. 2003. Vol. 420. P. 237–245.
  17. Papp J.G., Pollesello P., Varró A.F., Végh A.S. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion – induced arrhythmias in dogs // J. Cardiovasc. Pharmacol. Ther. 2006. Vol. 11. P. 129–135.
  18. Metzsch C., Liao Q., Steen S., Algotsson L. Levosimendan cardio-protection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model // Acta Anaesthesiol. Scand. 2007. Vol. 51. P. 86–93.
  19. Kersten J.R., Montgomery M.W., Pagel P.S., Warltier D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels // Anesth. Analg. 2000. Vol. 90. P. 5–11.
  20. Camici P.G., Prasad S.K., Rimoldi O.E., Stunning, hibernation, and assessment of myocardial viability // Circulation. 2008. Vol. 117. P. 103–114.
  21. Sonntag S., Sundberg S., Lehtonen L.A., Kleber F.X., The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia // J. Am. Coll. Cardiol. 2004. Vol. 43. P. 2177–2182.
  22. Wu X., Wu J., Yan X., Zhang Y. Enhancement of myocardial function and reduction of injury with levosimendan after percutaneous coronary intervention for acute myocardial infarction: a pilot study // Cardiology, 2014. Vol. 128. P. 202–208.
  23. Husebye T., Eritsland J., Müller C. et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study // Eur. J. Heart Fail. 2013. Vol. 15. P. 565–572.
  24. Hein M., Roehl A.B., Baumert J.H., Scherer K., Steendijk P., Rossaint R. Anti-ischemic effects of inotropic agents in experimental right ventricular infarction // Acta Anaesthesiol. Scand. 2009. Vol. 53. P. 941–948.
  25. Kivikko M., Antila S., Eha J., Lehtonen L., Pentikäinen P.J. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure // Int. J. Clin. Pharmacol. Ther. 2002. Vol. 40. P. 465–471.
  26. Lilleberg J., Laine M., Palkama T., Kivikko M., Pohjanjousi O., Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure // Eur. J. Heart Fail. 2007. Vol. 9. P. 75–82.
  27. Eriksson H.I., Jalonen J.R., Heikkinen L.O. et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function // Ann. Thorac. Surg. 2009. Vol. 87. P. 448–454.
  28. DeHert S.G., Lorsomradee S., Cromheecke S., VanderLinden P.J. The effects of levosimendan in cardiac surgery patients with poor left ventricular function // Anesth. Analg. Vol. 2007. 104. P. 766–773.
  29. Tritapepe L., DeSantis C., Vitale D. et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery // Br.J. Anaesth. Vol. 2009. 102. P. 198–204.
  30. Levin R., Degrange M., Del Mazo C., Tanus E., Porcile R. Preope-rative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass // Exp. Clin. Cardiol. 2012. Vol. 17. P. 125–130.
  31. Leppikangas H., Järvelä K., SistoT. et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery // Br. J. Anaesth. 2011. Vol. 106. P. 298–304.
  32. Lilleberg J., Nieminen M.S., Akkila J. et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting // Eur. Heart J. 1998. Vol. 19. P. 660–668.
  33. Levin R.L., Degrange M.A., Porcile R. et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome // Rev. Esp. 2008. Cardiol. Vol. 61. P. 471–479.
  34. Lahtinen P., Pitkänen O., Pölönen P., Turpeinen A., KiviniemiV. Uusaro A. Levosimendan reduces heart failure after cardiac surgery – a prospective, randomised, placebo-controlled trial // Crit. Care Med. 2011. Vol. 39. P. 2263–2270.
  35. Järvelä K., Maaranen P., Sisto T., Ruokonen E., Levosimendan in aortic valve surgery: cardiac performance and recovery // J. Cardiothorac. Vasc. Anesth. 2008. Vol. 22. P. 693–698.
  36. Jörgensen K., Bech-Hanssen O., Houltz E., Ricksten S.E. Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis // Circulation. 2008. Vol. 117. P. 1075–1081.
  37. Severi L., Lappa A., Landoni G. et al. Levosimendan versus intra-aortic balloon pump in high-risk cardiac surgery patients // J. Cardiothorac. Vasc. Anesth. 2011. Vol. 25. P. 632–636.
  38. Gandham R., Syamasundar A., Ravulapalli H. et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair/replacement for severe mitral stenosis // Ann. Card. Anaesth. 2013. Vol. 16. P. 11–15.
  39. Barisin S., Husedzinovic I., Sonicki Z., Bradic N., Barisin A. Tonkovic D. Levosimendan in off-pump coronary artery bypass: a four times masked controlled study // J. Cardiovasc. Pharmacol. 2004. Vol. 44. P. 703–708.
  40. Husedzinović I., Barisin S., Bradić N., Barisin A., Sonicki Z., Milanović R. Levosimendan as a new strategy during off-pump coronary artery bypass grafting: double blind, randomised, placebo-controlled trial // Croat. Med. J. 2005. Vol. 46. P. 950–956.
  41. Kodalli R.K., Sundar A.S., Vakamudi M. et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study // Ann. Card. Anaesth. 2013. Vol. 16. P. 94–99.
  42. Shah B., Sharma P., Brahmbhatt A. et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study // Indian J. Pharmacol. 2014. Vol. 46. P. 29–34.
  43. Bragadottir G., Redfors B., Ricksten S.E. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study // Crit. Care Med. 2013. Vol. 41. P. 2328–2335.
  44. Baysal A., Yanartas M., Dogukan M., Gundogus N., Kocak T., Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial // J. Cardiothorac. Vasc. Anesth. 2014. Vol. 28. P. 586–594.
  45. Yilmaz M.B., Grossini E., Silva Cardoso J.C. et al. Renal effects of levosimendan: a consensus report // Cardiovasc. Drugs Ther. 2013. Vol. 27. P. 581–590.
  46. Alvarez J., Baluja A., Selas S. et al. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomized controlled study // Anaesth. Intensive Care. 2013. Vol. 41. P. 719–727.
  47. Nieminen M.S., Fruhwald S., Heunks L.M. et al. Levosimendan: current data, clinical use, and future development // Heart Lung Vessel. 2013. Vol. 5. P. 227–245.
  48. Sponga S., Ivanitskaia E., Potapov E., Krabatsch T., Hetzer R., Lehmkuhl H. Preoperative treatment with levosimendan in candidates for mechanical circulatory support // ASAIOJ. 2012. Vol. 58. P. 6–11.
  49. Theiss H.D., Grabmaier U., Kreissl N. et al. Preconditioning with levosimendan before implantation of left ventricular assist devices // Artif. Organs. 2014. Vol. 38. P. 231–234.
  50. Labriola C., Siro-Brigiani M., Carrata F., Santangelo E., Amantea B., Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery // Int. J. Clin. Pharmacol. Ther. 2004. Vol. 42. P. 204–211.
  51. de Lissovoy G., Fraeman K., Teerlink J.R., Mullahy J., Salon J., Sterz R., Durtschi A., Padley R.J. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study // Eur. J. Health Econ. 2010. Vol. 11(2). P. 185–193.
  52. Cleland J.G., Takala A., Apajasalo M., Zethraeus N., Kobelt G., Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low output heart failure: an analysis based on the international LIDO trial // Eur. J. Heart Fail. 2003. Vol. 5 (1). P. 101–108.
  53. Lucioni C., D’Ambrosi A., Mazzi S., Pollesello P., Apajasalo M. Fedele F. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy // Adv. Ther. 2012. Vol. 29 (12). P. 1037–1050.
  54. Akgul A., Mavioglu L., Katircioglu S.F., Pac M., Cobanoglu A. Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting // Heart Lung Circ. 2006. Vol. 15. P. 320–324.
  55. Eris C., Yavuz S., Toktas F. et al. Preoperative usages of levosi-mendan in patients undergoing coronary artery bypass grafting (CABG, LVEF<30%) // Int. J. Clin. Exp. Med. 2014. Vol. 7. P. 219–229.
  56. Zangrillo A., Biondi-Zoccai G., Mizzi A. et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies // J. Cardiothorac. Vasc. Anesth. 2009. Vol. 23. P. 474–478.
  57. Landoni G., MizziA., Biondi-Zoccai G. et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials // J. Cardiothorac. Vasc. Anesth. 2010. Vol. 24. P. 51–57.
  58. Maharaj R., Metaxa V. Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomized controlled trials // Crit. Care. 2011. Vol. 15. R140.
  59. Niu Z.Z., Wu S.M., Sun W.Y., Hou W.M., Chi Y.F. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis // J. Cardiovasc. Pharmacol. 2014. Vol. 63. P. 107–112.